Boosting low white blood cells in blood cancer patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two medicines—thymalfasin and IL-2—to see if they can help raise low white blood cell counts (lymphocytes) in people with blood cancers. If you have low lymphocytes from your cancer or its treatment, this study may offer a way to boost your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer (like leukemia, lymphoma, or multiple myeloma).
- Your lymphocyte count or CD4+ T-cell count must be low (a simple blood test will show this).
- You must be 18 or older and expected to live at least 3 more months.
- Your kidneys and liver must be working fairly well (checked by blood tests).
- You should not have an active autoimmune disease, HIV, or active hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial tests whether thymosin alpha-1, an immune-boosting medicine, can help people with stage I non-small cell lung cancer after surgery. The goal is to see if it improves the immune system's response and recovery.
This trial tests whether the drug interferon alfa can help prevent blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancer (MDS or AML with a TP53 mutation) who had no detectable cancer cells when checked after transplant.
This Phase 2 trial looks at a transplant approach that reduces harmful immune cells (T cells) before or during an allogeneic stem cell transplant. It may help lower the risk of transplant complications while still letting the donor immune system fight the blood cancer.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.